Bristol Myers Squibb’s CAR-T Therapy Breyanzi Wins Broader Use

The FDA has broadened use of Bristol Myers Squibb’s Breyanzi, clearing it for use treating certain relapsed or refractory cases of marginal zone lymphoma. The new approval makes Breyanzi the first cell therapy available for the rare, slow-growing lymphatic tumor, which is believed to account for about 7% of all B-cell non-Hodgkin lymphoma cases.